Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial
Primary result · HbA1cResult — go to the resultAdjusted mean difference −0.8 % 95% CI −1.0 to −0.6Authors' conclusion
Results from this trial show the clinical efficacy of direct transition from multiple daily injections to tubeless AID in adults and children with type 1 diabetes, with no safety concerns, supporting AID as a therapeutic option within standard of care for people with type 1 diabetes.
Study context
- Population
- Participants aged 4–70 years with T1D on MDI and CGM, HbA1c 7.5–11% (58–97 mmol/mol); 19 hospitals in the UK, Belgium and Francerandomised 2:1
- Participants
- 188 participants
- Comparison
- Tubeless automated insulin delivery (AID) vs MDI
- AIDn = 125
- Controln = 63reference
- Primary endpoint
- Adjusted between-group difference in HbA1c, assessed for superiority
- Follow-up
- 13 weeks
Methodological detailsmulticentre, international, parallel-group, open-label
- Multicentre
- International
- Parallel-group
- Open-label
Primary result
HbA1c
Adjusted mean difference
−0.8 %
95% CI −1.0 to −0.6
P < 0.0001
By group
AIDvs Control
adjusted mean difference −0.8 % (95% CI −1.0 to −0.6); P < 0.0001
As reported in the abstract
Safety
| Outcome | AID | Control |
|---|---|---|
| Adverse eventsEvents = participants with adverse events | ||
| Adverse events | 39 | 3 |
| Serious adverse events | 2 events | — not stated in the abstract |
— not stated in the abstract
Severe hypoglycaemia or DKA · 13 weeks
- No episodes of severe hypoglycaemia or DKA in either group
Serious adverse events
- Kawasaki disease and acute coronary syndrome, unrelated to device or procedure
Original publication
Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial. Lancet Diabetes Endocrinol. Published 23 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →